Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
Overview of ResMed
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in healthcare technology, specializing in cloud-connected medical devices and digital health solutions that transform care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases. By harnessing cutting-edge technology, ResMed empowers patients to live healthier, higher-quality lives while reducing the burden on healthcare systems.
Core Business Areas
ResMed’s core business revolves around two primary segments:
- Medical Devices: ResMed designs and manufactures flow generators, masks, and accessories for the treatment of sleep apnea and other respiratory conditions. These devices are cloud-enabled, allowing for real-time data collection and analysis to improve patient adherence and outcomes.
- Out-of-Hospital Software Platforms: ResMed provides software solutions that support professionals and caregivers in managing patient care outside of traditional hospital settings. These platforms are integral to enabling home-based care and optimizing healthcare delivery.
Market Position and Industry Context
ResMed operates within the growing healthcare technology industry, addressing the increasing prevalence of sleep apnea, COPD, and other chronic diseases driven by aging populations and rising obesity rates. The company distinguishes itself through its focus on digital health integration, leveraging clinical data to improve patient outcomes and reduce costs. ResMed’s products and solutions are utilized in over 140 countries, with a significant portion of its revenue generated in the Americas, followed by Europe, Japan, and Australia.
Competitive Landscape
ResMed faces competition from other healthcare technology companies specializing in respiratory care and digital health solutions. However, its unique value proposition lies in combining hardware and software to deliver comprehensive, connected care. By prioritizing innovation and integrating patient-centric features, ResMed has positioned itself as a trusted provider in its field.
Revenue Model
ResMed generates revenue through the direct sale of medical devices, subscriptions to its software platforms, and licensing agreements. Its cloud-connected devices and digital solutions enable recurring revenue streams, particularly through data-driven insights that benefit patients, healthcare providers, and payers.
Challenges and Opportunities
ResMed faces challenges such as navigating regulatory environments, managing competition, and ensuring continuous innovation. However, opportunities abound in the growing demand for digital health solutions, increasing awareness of sleep health, and expanding markets for home-based care.
Why ResMed Matters
ResMed’s commitment to improving quality of life while reducing healthcare costs makes it a significant player in the healthcare technology industry. Its focus on connected health solutions aligns with broader industry trends, emphasizing preventative care and personalized patient experiences. By addressing critical health issues like sleep apnea and COPD, ResMed contributes to better health outcomes and reduced economic burden on global healthcare systems.
On August 25, 2021, Supermoon Capital launched a $36 million venture fund focused on early-stage startups innovating in the sleep sector. This fund is the first of its kind, targeting the growing 'Night Market™,' which is valued at $488 billion. Co-founded by Pat Connolly and Michael Masterson, the fund aims to address significant sleep issues affecting 75% of Americans. Investments include six startups, such as Clair Labs and Endel, aimed at improving sleep health through science-backed innovations.
ResMed has launched AirSense 11, a next-generation PAP device aimed at enhancing sleep apnea therapy. First available in the U.S., this device features a Personal Therapy Assistant and Care Check-In tools via the myAir app, improving patient engagement and adherence. The device is designed for user comfort with a sleek design and intuitive interface. Patient adherence is reported at 87%. AirSense 11 is compatible with all ResMed masks and offers remote upgrades for its software, reinforcing its commitment to digital health.
ResMed (NYSE: RMD) reported a strong fourth quarter for fiscal 2021, with revenue rising 14% to $876.1 million. Operating profit increased 8%, while non-GAAP operating profit rose 7%. Full-year revenue also grew 8% to $3.2 billion, with non-GAAP diluted EPS at $5.33. The gross margin contracted, mainly due to a shift in product mix. An 8% dividend increase to $0.42 per share was announced. CEO Mick Farrell highlighted recovery in core sleep apnea and COPD patient flow despite challenges from prior COVID-19 ventilator sales. A virtual Investor Day is scheduled for September 8, 2021.
ResMed (NYSE: RMD) will release its fourth quarter fiscal year 2021 financial results on August 5, 2021, after NYSE closure. A webcast to discuss these results will follow, providing essential insights into the company's performance and future outlook. The event starts at 1:30 p.m. PDT / 4:30 p.m. EDT. Interested parties can access the details via ResMed's investor page. A replay will be available shortly after the session, continuing until August 19, 2021.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. EDT. The chat will be available via a live video webcast, with a replay accessible approximately 12 hours after the event, remaining available until June 8, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve quality of life and lower healthcare costs globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 1:20 p.m. CDT. The event will be accessible via video webcast, with a replay available approximately 24 hours after the event and lasting until July 1, 2021. ResMed focuses on innovative solutions for chronic diseases, helping improve patient quality of life and reduce healthcare costs worldwide.
ResMed (NYSE: RMD) reported its third-quarter fiscal 2021 results, revealing a 3% year-over-year increase in net operating profit but a non-GAAP revenue drop to $768.8 million, down 3% on a constant currency basis. The GAAP diluted EPS was $(0.54), compared to $1.12 last year, primarily due to a $255 million reserve related to tax disputes. Non-GAAP diluted EPS rose by 1% to $1.30. Additionally, operational cash flow was $196.3 million, and a quarterly cash dividend of $0.39 per share was declared.
ResMed (NYSE: RMD) announced that CFO Brett Sandercock will present virtually at the Macquarie Australia Conference on May 5, 2021, at 8:45 a.m. AEST. This event will be accessible via video webcast, with a replay available for Macquarie clients 24 hours post-event until May 26, 2021. ResMed is known for its innovative digital health technologies and cloud-connected devices aimed at improving care for chronic diseases like sleep apnea and COPD, effectively transforming healthcare delivery worldwide.
ResMed plans to release its third-quarter fiscal year 2021 financial results on April 29, 2021, post-market closure. The earnings call will be hosted by management at 1:30 p.m. PDT (4:30 p.m. EDT) with an international audience included. A webcast link for the earnings results is provided for stakeholders. A replay of the webcast will be available shortly after, with a phone replay accessible until May 13, 2021. ResMed is committed to providing innovative healthcare solutions for chronic diseases worldwide, with operations in over 140 countries.
ResMed (NYSE: RMD) has announced that Rob Douglas, president and COO, and Brett Sandercock, CFO, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2021, at 4:15 p.m. EDT. The event will be accessible via a video webcast. A replay will be available one hour post-event until June 21, 2021. ResMed focuses on innovative solutions to treat chronic diseases, providing digital health technologies and cloud-connected medical devices that enhance the quality of life for patients globally.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
What does ResMed specialize in?
How does ResMed generate revenue?
What makes ResMed unique in the healthcare technology industry?
What are ResMed’s core business areas?
In which regions does ResMed operate?
What challenges does ResMed face in its market?
How does ResMed contribute to healthcare cost reduction?
What conditions does ResMed’s technology address?
What is ResMed’s competitive advantage?
How does ResMed support out-of-hospital care?
